Alychlo investing in potential breakthroughs of cancer treatments
11 February 2021
Share this article
Droia Ventures has supported Series C financing of Cyteir Therapeutics for the advance Clinical Trials of Lead RAD51, a potential breakthrough forcancer treatments.
Alychlo is a proud partner of Droia since 2014 and has supported Droia in each of their funds since then.
Find the full press release on:
